STOCK TITAN
  1. Home
  2. Sec-filings
  3. PROF
  4. [8-K] Profound Medical Corp. Reports Material Event

Profound Medical (NASDAQ: PROF) plans business update at 2026 Bloom Burton healthcare investor conference

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Profound Medical Corp. filed a current report describing its participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference. Management will present a business update on April 22, 2026, at 10:00 a.m. Eastern Time in Toronto, with a live and archived webcast on the company’s website.

The filing includes the related press release as an exhibit and notes that this information is furnished under Regulation FD, meaning it is provided for fair disclosure rather than as part of the company’s formally filed financial statements.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Conference presentation date April 22, 2026 Bloom Burton & Co. Healthcare Investor Conference
Presentation time 10:00 a.m. Eastern Time Business update session at conference
Press release date April 14, 2026 Date of Profound Medical’s conference participation announcement
Investor relations phone 647.872.4849 Contact number for investor relations inquiry
Regulation FD regulatory
"Item 7.01. Regulation FD Disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
commercial-stage medical device company financial
"Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures"
MRI-guided, incision-free therapies technical
"develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue"
ablation of diseased tissue medical
"incision-free therapies for the ablation of diseased tissue"
benign prostatic hyperplasia (BPH) medical
"including prostate cancer and/or benign prostatic hyperplasia (BPH)"
Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms such as weak stream, frequent nighttime urination, or difficulty starting. Investors care because BPH is common in older men, creating steady demand for medications, medical devices, and procedures; changes in treatment options, regulatory approvals, or trial results can affect companies that sell therapies — think of it as a market driven by a widespread, age-related ‘traffic jam’ in the urinary system.
Understanding 8-K Material Events →
False000162880800016288082026-04-142026-04-14iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  April 14, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada001-39032Not Applicable
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

 

 

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common SharesPROFThe Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
Item 7.01. Regulation FD Disclosure.

 

On April 14, 2026, Profound Medical Corp. (the “Company” or “Profound”) issued a press release announcing that the Company will present an update on the Company’s business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026, at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre and via live broadcast. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.Description
99.1Press Release, dated April 14, 2026
104Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 
 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 PROFOUND MEDICAL CORP.
   
  
Date: April 14, 2026By: /s/ Rashed Dewan        
  Rashed Dewan
  Chief Financial Officer
  

 

EXHIBIT 99.1

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "IR Calendar" in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.

The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

Source: View Original Filing on SEC EDGAR

FAQ

What did Profound Medical Corp. (PROF) announce in this 8-K filing?

Profound Medical Corp. announced that management will present a business update at the 2026 Bloom Burton & Co. Healthcare Investor Conference. The session occurs April 22, 2026, 10:00 a.m. Eastern Time, in Toronto and will be broadcast live and archived on the company’s website.

When and where will Profound Medical (PROF) present at the 2026 Bloom Burton conference?

Profound Medical will present on April 22, 2026, at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will also be accessible via live webcast and later archived under the IR Calendar on the company’s website.

How can investors access Profound Medical’s Bloom Burton 2026 presentation?

Investors can access Profound Medical’s presentation through a live broadcast on the company’s website, www.profoundmedical.com, under the “IR Calendar” in the Investors section. The webcast will also be archived there for later viewing after the live event concludes.

What type of company is Profound Medical Corp. (PROF) according to this filing?

Profound Medical is described as a commercial-stage medical device company focused on AI-powered, MRI-guided, incision-free therapies for ablation of diseased tissue. Its technologies aim to improve clinical confidence, procedural control, and patient outcomes through precise, real-time MRI-guided treatment approaches.

Which flagship products of Profound Medical (PROF) are highlighted in the disclosure?

The disclosure highlights TULSA-PRO, enabling MRI-guided, incision-free prostate therapy, and Sonalleve, an MRI-guided therapy for pain palliation of bone metastases, desmoid tumors, osteoid osteoma, and gynecologic conditions like uterine fibroids and adenomyosis, offering non-surgical, uterine-sparing treatment options.

Is the Bloom Burton conference information considered filed financial information for Profound Medical (PROF)?

No. The 8-K states that the information under Item 7.01, including the press release, is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Filing Exhibits & Attachments

5 documents

Press Releases

Other Documents